Nova Eye MedicalELXMF -0.03%55 PB Ratio is 0.39 as of Jun. 29, 2026, which is 73% below its 10-year median of 1.44. GuruFocus rates ELXMF with a GF Score™ of 55/100 and a GF Value™ of $0.02. The stock has 4 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Nova Eye Medical ranks better than 53.94% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), Nova Eye Medical's share price is $0.01431. Nova Eye Medical's Book Value per Share for the quarter that ended in Dec. 2025 was $0.04. Hence, Nova Eye Medical's PB Ratio of today is 0.39.
The historical rank and industry rank for Nova Eye Medical's PB Ratio or its related term are showing as below:
ELXMF'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 1.44 Max: 3.73
Current: 1.88
During the past 13 years, Nova Eye Medical's highest PB Ratio was 3.73. The lowest was 0.43. And the median was 1.44.
ELXMF's PB Ratio is ranked better than 53.94% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 2.015
vs ELXMF: 1.88
During the past 12 months, Nova Eye Medical's average Book Value Per Share Growth Rate was -26.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -30.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -34.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -17.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Nova Eye Medical was 61.30% per year. The lowest was -44.10% per year. And the median was -1.15% per year.
Back to Basics: PB Ratio
Nova Eye Medical (OTCPK:ELXMF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Nova Eye Medical PB Ratio Related Terms
Nova Eye Medical PB Ratio Historical Data
* Premium members only.
The historical data trend for Nova Eye Medical's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nova Eye Medical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nova Eye Medical (ELXMF) has a PB Ratio of 0.39 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nova Eye Medical and its competitors. This is 73% below median its historical median of 1.44. Over the past decade, Nova Eye Medical's PB Ratio has ranged from 0.43 to 3.73. According to the industry distribution chart, Nova Eye Medical ranks #362 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 46.1%.
Is Nova Eye Medical's PB Ratio too high?
Nova Eye Medical's current PB Ratio of 0.39 is 73% below median its 10-year median of 1.44. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 3.73. The Medical Devices & Instruments industry median PB Ratio is 2.02. Nova Eye Medical's value of 0.39 is 80.6% below this industry median. Based on the distribution chart, Nova Eye Medical ranks #362 out of 786 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nova Eye Medical has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #362 out of 786 companies for PB Ratio. This puts Nova Eye Medical in the upper half of its industry. The industry median PB Ratio is 2.02. Nova Eye Medical's value of 0.39 is 80.6% below this benchmark. Historically, Nova Eye Medical's own PB Ratio has ranged from 0.43 to 3.73 over the past decade. While the company's 10-year median is 1.44 vs. the industry median of 2.02, Nova Eye Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Eye Medical's current PB Ratio of 0.39 is 80.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nova Eye Medical and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current PB Ratio is 0.39, which is 73% below median its own 10-year median of 1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Nova Eye Medical (ELXMF) has a current PB Ratio of 0.39. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 28.5% below its estimated fair value. The current PB Ratio is 0.39, which is 73% below median its 10-year median of 1.44 and 80.6% below the Medical Devices & Instruments industry median of 2.02. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Nova Eye Medical (ELXMF), the current PB Ratio is 0.39 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ELXMF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of $0.01 is trading 28.5% below its estimated GF Value™ of $0.02.
Key valuation signals for ELXMF:
PB Ratio: 0.39 (73% below median its 10-year median of 1.44)
GF Value™: $0.02 vs. price of $0.01 (28.5% below fair value)
Industry Position: 80.6% below the Medical Devices & Instruments median (#362 of 786)
No single metric tells the full story. See the ELXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score
Get the complete analysis for ELXMF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELXMF has been successfully added to your 
